- Joined
- Aug 14, 2010
- Messages
- 572
The addition of antitumor necrosis factor-α (TNF-α) agents to the therapeutic armamentarium against Crohn’s disease has been a revolution in its management.
However, approximately 25 to 40% of patients who initially benefit from anti-TNF-α treatment develop intolerable adverse events or loose their response during maintenance therapy.
Drs Reinisch and Danese summarized the current knowledge on the mechanisms underlying loss of response in these patients and the therapeutic strategies available to counteract this clinical challenge.
The team performed a literature search using PubMed, MedLine and Embase databases.
Anti-infliximab antibodies formation and autoantibodies have been associated with loss of response.
The research team found that individual differences in drug metabolism may contribute to loss of response.
The team observed that smoking may be a risk factor for loss of response.
Dose escalation, reduction of infusion intervals and switch to other anti-TNF-α agents are effective as rescue strategies.
Dr Reinisch and colleague concluded, "Loss of response appears to result from different causes not fully established by now."
"Optimization of therapies, or switch to other anti-TNF-α, are currently the best studied strategies in case of loss of response, and can be successful in 40–60% of patients who lose response."
Smoking may be a risk factor for loss of response
http://www.gastrohep.com/news/news.asp?id=108095
However, approximately 25 to 40% of patients who initially benefit from anti-TNF-α treatment develop intolerable adverse events or loose their response during maintenance therapy.
Drs Reinisch and Danese summarized the current knowledge on the mechanisms underlying loss of response in these patients and the therapeutic strategies available to counteract this clinical challenge.
The team performed a literature search using PubMed, MedLine and Embase databases.
Anti-infliximab antibodies formation and autoantibodies have been associated with loss of response.
The research team found that individual differences in drug metabolism may contribute to loss of response.
The team observed that smoking may be a risk factor for loss of response.
Dose escalation, reduction of infusion intervals and switch to other anti-TNF-α agents are effective as rescue strategies.
Dr Reinisch and colleague concluded, "Loss of response appears to result from different causes not fully established by now."
"Optimization of therapies, or switch to other anti-TNF-α, are currently the best studied strategies in case of loss of response, and can be successful in 40–60% of patients who lose response."
Smoking may be a risk factor for loss of response
http://www.gastrohep.com/news/news.asp?id=108095
